Floatz logo

Tagitanlimab

Advanced Solid Tumors

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.monoclonal_antibodyPhase 1Active
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
59/ 100

Competitive context

435 Active assets in the Advanced Solid Tumors cohort.

Asset / SponsorPhaseRating
Eloxatin
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 4BB
FLUOROURACILUM
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
InSilico Medicine Hong Kong Limited
Phase 4BB
Irinotecan
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Calcium folinate pentahydrate
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB

View all 50 →

Same molecule, other indications

Tagitanlimab is also rated in:

Prostate Adenocarcinoma With Neuroendocrine DifferentiationDormant
CCC
Indicative ·
53 / 100
View asset →
castration-resistant prostate carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
prostate adenocarcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →